These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 8011749)

  • 21. [Synergetic responses after administration of interleukin-2 and Interferon-alpha combined with gamma knife radiosurgery in a patient with multiple lung and brain metastases: a case report].
    Takada T; Yamada Y; Uno M; Komeda H; Fujimoto Y
    Hinyokika Kiyo; 2005 Jun; 51(6):381-4. PubMed ID: 16050476
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multifocal metastases of recurrent renal cell carcinoma successfully treated with a combination of low dose interleukin-2, alpha-interferon and radiotherapy.
    Sawada N; Fukasawa M; Araki I; Kira S; Manabu K; Takeda M
    Int J Urol; 2005 Nov; 12(11):994-5. PubMed ID: 16351657
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Cytokine treatment of renal cell carcinoma].
    Tazaki H
    Gan To Kagaku Ryoho; 1994 Jan; 21(1):29-36. PubMed ID: 8291913
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute right ventricular heart failure in a patient with renal cell carcinoma after interferon therapy.
    Kramers C; de Mulder PH; Barth JD; Wagener DJ
    Neth J Med; 1993 Feb; 42(1-2):65-8. PubMed ID: 8446228
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A case of advanced renal cell carcinoma achieved complete response by a sequential combination therapy with gamma interferon and OK-432 (streptococcal preparation)].
    Nakamura S; Marumo K; Shibayama T; Baba S; Deguchi N; Tazaki H
    Nihon Hinyokika Gakkai Zasshi; 1988 Jun; 79(6):1103-7. PubMed ID: 3141666
    [No Abstract]   [Full Text] [Related]  

  • 26. Response to 13-cis-retinoic acid plus interferon alfa-2a in two patients with therapy-refractory advanced renal cell carcinoma.
    Buer J; Probst M; Ganser A; Atzpodien J
    J Clin Oncol; 1995 Oct; 13(10):2679-80. PubMed ID: 7595723
    [No Abstract]   [Full Text] [Related]  

  • 27. Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma.
    Clark PE; Hall MC; Miller A; Ridenhour KP; Stindt D; Lovato JF; Patton SE; Brinkley W; Das S; Torti FM
    Urology; 2004 Jun; 63(6):1061-5. PubMed ID: 15183950
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [First-line therapy for German patients with metastatic kidney neoplasms in EORTC-Protocol 30012].
    Rexer H
    Urologe A; 2004 Aug; 43(8):992-3. PubMed ID: 15316609
    [No Abstract]   [Full Text] [Related]  

  • 29. Adjuvant interleukin-2, interferon-alpha, and 5-fluorouracil immunochemotherapy after radical nephrectomy for locally advanced renal cell carcinoma.
    Hong SK; Kwak C; Lee SE
    Urology; 2005 Sep; 66(3):518-22. PubMed ID: 16140069
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Medical treatment options in patients with metastatic renal cell carcinoma.
    Haferkamp A; Hohenfellner M
    Nephrol Dial Transplant; 2007 Apr; 22(4):996-9. PubMed ID: 17210591
    [No Abstract]   [Full Text] [Related]  

  • 31. Renal cancer: Genetic directed therapy.
    Loughlin KR
    Urol Oncol; 2009; 27(2):130. PubMed ID: 19285229
    [No Abstract]   [Full Text] [Related]  

  • 32. Immunotherapy and prognostic factors.
    Fumagalli LA; Brivio F
    J Clin Oncol; 2006 Sep; 24(25):4218-9; author reply 4219-20. PubMed ID: 16943541
    [No Abstract]   [Full Text] [Related]  

  • 33. A phase II trial of interferon-alpha and 5-fluorouracil in patients with advanced renal cell carcinoma. A Southwest Oncology Group study.
    Elias L; Blumenstein BA; Kish J; Flanigan RC; Wade JL; Lowe BA; Goodwin JW; Crawford ED
    Cancer; 1996 Sep; 78(5):1085-8. PubMed ID: 8780547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapy for metastatic renal cell carcinoma.
    McDermott DF; Rini BI
    BJU Int; 2007 May; 99(5 Pt B):1282-8. PubMed ID: 17441925
    [No Abstract]   [Full Text] [Related]  

  • 35. Integrative tumor board: metastatic renal cell carcinoma: medical oncology.
    Gupta SK; Vogelzang N
    Integr Cancer Ther; 2004 Mar; 3(1):26-9. PubMed ID: 15035871
    [No Abstract]   [Full Text] [Related]  

  • 36. Outpatient treatment with subcutaneous interleukin-2, interferon alpha and fluorouracil in patients with metastatic renal cancer: an Australian experience.
    Marx G; Taylor J; Goldstein D
    Intern Med J; 2005 Jan; 35(1):34-8. PubMed ID: 15667466
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Temsirolimus for advanced renal-cell carcinoma.
    Ferretti G
    N Engl J Med; 2007 Sep; 357(10):1050; author reply 1050-1. PubMed ID: 17823993
    [No Abstract]   [Full Text] [Related]  

  • 38. Tumor infiltrating dendritic cells predict treatment response to immmunotherapy in patients with metastatic renal cell carcinoma.
    Kobayashi M; Suzuki K; Yashi M; Yuzawa M; Takayashiki N; Morita T
    Anticancer Res; 2007; 27(2):1137-41. PubMed ID: 17465253
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Combination chemotherapy with 5-FU and low-dose CDDP for urogenital tumors].
    Fujinami K; Kubota Y
    Gan To Kagaku Ryoho; 1999 Oct; 26(11):1559-63. PubMed ID: 10553413
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997.
    Dutcher JP; Atkins M; Fisher R; Weiss G; Margolin K; Aronson F; Sosman J; Lotze M; Gordon M; Logan T; Mier J
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S73-8. PubMed ID: 9457399
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.